Ronald N Marcus1, Randall Owen2, Lisa Kamen1, George Manos1, Robert D McQuade1, William H Carson1, Michael G Aman1. 1. Drs. Marcus, Owen, Kamen, and Manos are with Bristol-Myers Squibb; Drs. McQuade and Carson are with Otsuka Pharmaceutical Development & Commercialization and Dr. Aman is with Ohio State University. 2. Drs. Marcus, Owen, Kamen, and Manos are with Bristol-Myers Squibb; Drs. McQuade and Carson are with Otsuka Pharmaceutical Development & Commercialization and Dr. Aman is with Ohio State University. Electronic address: randall.owen@bms.com.
Abstract
OBJECTIVE: To evaluate the short-term efficacy and safety of aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. METHOD: Two hundred eighteen children and adolescents (aged 6-17 years) with a diagnosis of autistic disorder, and with behaviors such as tantrums, aggression, self-injurious behavior, or a combination of these symptoms, were randomized 1:1:1:1 to aripiprazole (5, 10, or 15 mg/day) or placebo in this 8-week double-blind, randomized, placebo-controlled, parallel-group study. Efficacy was evaluated using the caregiver-rated Aberrant Behavior Checklist Irritability subscale (primary efficacy measure) and the clinician-rated Clinical Global Impressions-Improvement score. Safety and tolerability were also assessed. RESULTS: At week 8, all aripiprazole doses produced significantly greater improvement than placebo in mean Aberrant Behavior Checklist Irritability subscale scores (5 mg/day, -12.4; 10 mg/day, -13.2; 15 mg/day, -14.4; versus placebo, -8.4; all p < .05). All aripiprazole doses demonstrated significantly greater improvements in mean Clinical Global Impressions-Improvement score than placebo at week 8. Discontinuation rates due to adverse events were as follows: placebo 7.7%, aripiprazole 5 mg/day 9.4%, 10 mg/day 13.6%, and 15 mg/day 7.4%. The most common adverse event leading to discontinuation was sedation. There were two serious adverse events: presyncope (5 mg/day) and aggression (10 mg/day). At week 8, mean weight change (last observation carried forward) was as follows: placebo +0.3 kg, aripiprazole 5 mg/day +1.3 kg, 10 mg/day +1.3 kg, and 15 mg/day +1.5 kg; all p < .05 versus placebo. CONCLUSIONS:Aripiprazole was efficacious and generally safe and well tolerated in the treatment of children and adolescents with irritability associated with autistic disorder.
RCT Entities:
OBJECTIVE: To evaluate the short-term efficacy and safety of aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. METHOD: Two hundred eighteen children and adolescents (aged 6-17 years) with a diagnosis of autistic disorder, and with behaviors such as tantrums, aggression, self-injurious behavior, or a combination of these symptoms, were randomized 1:1:1:1 to aripiprazole (5, 10, or 15 mg/day) or placebo in this 8-week double-blind, randomized, placebo-controlled, parallel-group study. Efficacy was evaluated using the caregiver-rated Aberrant Behavior Checklist Irritability subscale (primary efficacy measure) and the clinician-rated Clinical Global Impressions-Improvement score. Safety and tolerability were also assessed. RESULTS: At week 8, all aripiprazole doses produced significantly greater improvement than placebo in mean Aberrant Behavior Checklist Irritability subscale scores (5 mg/day, -12.4; 10 mg/day, -13.2; 15 mg/day, -14.4; versus placebo, -8.4; all p < .05). All aripiprazole doses demonstrated significantly greater improvements in mean Clinical Global Impressions-Improvement score than placebo at week 8. Discontinuation rates due to adverse events were as follows: placebo 7.7%, aripiprazole 5 mg/day 9.4%, 10 mg/day 13.6%, and 15 mg/day 7.4%. The most common adverse event leading to discontinuation was sedation. There were two serious adverse events: presyncope (5 mg/day) and aggression (10 mg/day). At week 8, mean weight change (last observation carried forward) was as follows: placebo +0.3 kg, aripiprazole 5 mg/day +1.3 kg, 10 mg/day +1.3 kg, and 15 mg/day +1.5 kg; all p < .05 versus placebo. CONCLUSIONS:Aripiprazole was efficacious and generally safe and well tolerated in the treatment of children and adolescents with irritability associated with autistic disorder.
Authors: Thomas W Frazier; Paul T Shattuck; Sarah Carter Narendorf; Benjamin P Cooper; Mary Wagner; Edward L Spitznagel Journal: J Child Adolesc Psychopharmacol Date: 2011-12-13 Impact factor: 2.576
Authors: Janet L Kowalski; Logan K Wink; Kelly Blankenship; Cheryl D Habenicht; Craig A Erickson; Kimberly A Stigler; Christopher J McDougle Journal: J Child Adolesc Psychopharmacol Date: 2011-10 Impact factor: 2.576
Authors: Lawrence Scahill; Christopher J McDougle; Michael G Aman; Cynthia Johnson; Benjamin Handen; Karen Bearss; James Dziura; Eric Butter; Naomi G Swiezy; L Eugene Arnold; Kimberly A Stigler; Denis D Sukhodolsky; Luc Lecavalier; Stacie L Pozdol; Roumen Nikolov; Jill A Hollway; Patricia Korzekwa; Allison Gavaletz; Arlene E Kohn; Kathleen Koenig; Stacie Grinnon; James A Mulick; Sunkyung Yu; Benedetto Vitiello Journal: J Am Acad Child Adolesc Psychiatry Date: 2011-12-23 Impact factor: 8.829
Authors: Constadina Panagiotopoulos; Rebecca Ronsley; Dean Elbe; Jana Davidson; Derryck H Smith Journal: J Can Acad Child Adolesc Psychiatry Date: 2010-05
Authors: Logan K Wink; Ernest V Pedapati; Ryan Adams; Craig A Erickson; Kahsi A Pedersen; Eric M Morrow; Desmond Kaplan; Matthew Siegel Journal: J Autism Dev Disord Date: 2018-11